GSK leverages Greater Bay Area patient data to accelerate drug development

GSK plans to use patient data from the Greater Bay Area's 88 million residents to support regulatory filings and drug development in vaccines and oncology, aligning with official efforts to enhance cross-border medical cooperation. The initiative highlights the growing role of real-world data in pharmaceutical R&D, though its impact on specific drug approvals remains uncertain. This marks a notable step in integrating regional health data for commercial purposes.